Literature DB >> 21248243

Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.

Hye Jung Kim1, Veronique E Miron, Danuta Dukala, Richard L Proia, Samuel K Ludwin, Maria Traka, Jack P Antel, Betty Soliven.   

Abstract

Fingolimod (FTY720) is a sphingosine 1-phosphate (S1P) receptor modulator that regulates lymphocyte trafficking and exerts pleiotropic actions on oligodendrocytes (OLGs) and other neural cells. The purpose of this study was to investigate the role of S1P receptors in a non-T-cell model of demyelination, the cuprizone (cupr) model in C57BL/6 mice. Treatment with FTY720 (1 mg/kg) led to attenuated injury to OLGs, myelin, and axons in the corpus callosum (percentage of myelinated fibers was 44.7% in cupr-water and 63% in cupr-FTY720). Reactive astrogliosis and microgliosis were ameliorated when FTY720 was given from d 1, but astrogliosis was augmented when FTY720 was given from wk 4-9. FTY720 did not promote remyelination in this model. The protective effect of FTY720 was associated with decreased interleukin-1β and CCL2 transcripts in the corpus callosum, as well as altered S1P1 expression. Targeted deletion of S1P1 in OLG lineage cells did not lead to obvious clinical phenotype, but resulted in subtle abnormalities in myelin and an increased susceptibility to cupr-induced demyelination. We conclude that S1P receptors expressed by neuroglia are involved in regulating the response to injury, and CNS effects of FTY720 could contribute to its favorable therapeutic response in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248243      PMCID: PMC3079302          DOI: 10.1096/fj.10-173203

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  61 in total

1.  Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination.

Authors:  J L Mason; J J Jones; M Taniike; P Morell; K Suzuki; G K Matsushima
Journal:  J Neurosci Res       Date:  2000-08-01       Impact factor: 4.164

2.  Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.

Authors:  Ruben Van Doorn; Jack Van Horssen; Dennis Verzijl; Maarten Witte; Eric Ronken; Bert Van Het Hof; Kim Lakeman; Christine D Dijkstra; Paul Van Der Valk; Arie Reijerkerk; Astrid E Alewijnse; Stephan L M Peters; Helga E De Vries
Journal:  Glia       Date:  2010-09       Impact factor: 7.452

3.  Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells.

Authors:  K Sato; K Ishikawa; M Ui; F Okajima
Journal:  Brain Res Mol Brain Res       Date:  1999-12-10

4.  Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination.

Authors:  J L Mason; P Ye; K Suzuki; A J D'Ercole; G K Matsushima
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

5.  FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.

Authors:  Ji Woong Choi; Shannon E Gardell; Deron R Herr; Richard Rivera; Chang-Wook Lee; Kyoko Noguchi; Siew Teng Teo; Yun C Yung; Melissa Lu; Grace Kennedy; Jerold Chun
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-21       Impact factor: 11.205

6.  Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.

Authors:  Sara Veto; Peter Acs; Jan Bauer; Hans Lassmann; Zoltan Berente; Gyorgy Setalo; Gabor Borgulya; Balazs Sumegi; Samuel Komoly; Ferenc Gallyas; Zsolt Illes
Journal:  Brain       Date:  2010-02-15       Impact factor: 13.501

7.  Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

Authors:  Veronique E Miron; Samuel K Ludwin; Peter J Darlington; Andrew A Jarjour; Betty Soliven; Timothy E Kennedy; Jack P Antel
Journal:  Am J Pathol       Date:  2010-04-22       Impact factor: 4.307

8.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

9.  FTY720 reduces inflammation and promotes functional recovery after spinal cord injury.

Authors:  Kangmin D Lee; Woon N Chow; Carmen Sato-Bigbee; Martin R Graf; Robert S Graham; Raymond J Colello; Harold F Young; Bruce E Mathern
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

10.  Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia.

Authors:  D Nayak; Y Huo; W X T Kwang; P N Pushparaj; S D Kumar; E-A Ling; S T Dheen
Journal:  Neuroscience       Date:  2009-12-28       Impact factor: 3.590

View more
  36 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.

Authors:  Yuan Zhang; Xing Li; Bogoljub Ciric; Cun-Gen Ma; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Ther       Date:  2016-12-28       Impact factor: 11.454

Review 3.  Regulation of lymphocyte trafficking in central nervous system autoimmunity.

Authors:  Mohamed Oukka; Estelle Bettelli
Journal:  Curr Opin Immunol       Date:  2018-09-27       Impact factor: 7.486

4.  Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease.

Authors:  Mona Lei; Jonathan D Teo; Huitong Song; Holly P McEwen; Jun Yup Lee; Timothy A Couttas; Thomas Duncan; Rose Chesworth; Josefine Bertz; Magdalena Przybyla; Janet Van Eersel; Benjamin Heng; Gilles J Guillemin; Lars M Ittner; Thomas Fath; Brett Garner; Arne Ittner; Tim Karl; Anthony S Don
Journal:  J Neurosci       Date:  2019-10-22       Impact factor: 6.167

Review 5.  Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.

Authors:  Natalie A Wheeler; Babette Fuss
Journal:  Exp Neurol       Date:  2016-03-23       Impact factor: 5.330

6.  [New therapeutic strategies for remyelination in multiple sclerosis].

Authors:  D Kremer; H-P Hartung; M Stangel; P Küry
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

7.  Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.

Authors:  Veit Rothhammer; Jessica E Kenison; Emily Tjon; Maisa C Takenaka; Kalil Alves de Lima; Davis M Borucki; Chun-Cheih Chao; Annabel Wilz; Manon Blain; Luke Healy; Jack Antel; Francisco J Quintana
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

Review 8.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 9.  Lysophospholipids and their receptors in the central nervous system.

Authors:  Ji Woong Choi; Jerold Chun
Journal:  Biochim Biophys Acta       Date:  2012-07-31

10.  Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit.

Authors:  Hongkai Wang; Chengren Li; Hanzhi Wang; Feng Mei; Zhi Liu; Hai-Ying Shen; Lan Xiao
Journal:  Neurosci Bull       Date:  2013-04-05       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.